DTX-861

DTX-861 is a novel, potent, and highly specific degrader of casein kinase 1 alpha (CK1 alpha). It is being investigated as a potential therapeutic for colorectal cancer (CRC), particularly in cases with activating mutations in the WNT/beta-catenin pathway, such as those with biallelic APC mutations. By degrading CK1 alpha, DTX-861 leads to WNT hyperactivation and enhanced beta-catenin signaling, which has been shown to reduce colony formation in APC-mutant CRC cell lines while sparing APC wild-type cells. Oral administration of DTX-861 has demonstrated robust in vivo efficacy, resulting in a dose-dependent reduction in CK1 alpha, induction of beta-catenin target gene expression, and tumor growth inhibition in multiple APC mutant CDX and PDX models of CRC. This mechanism leverages the concept of Activation Lethality, where cancers are vulnerable to further hyperactivation of oncogenic drivers.